subgroup of
antibiotic)
→
ReceivesAction
→
developed
| Typicality: | 0.532 |
| Saliency: | 1.000 |
| due to the lack of economic viability | 4 | cause |
| surprisingly | 3 | degree |
| by pharmaceutical companies | 2 | other |
| new antibiotic → be → developed | 40 |
| new antibiotic → be → created | 4 |
| new antibiotic → be in → development | 3 |
| negative | neutral | positive |
| 0.478 | 0.421 | 0.101 |
| Raw frequency | 47 |
| Normalized frequency | 1.000 |
| Modifier score | 0.320 |
| Perplexity | 294.907 |